Methadone

— THERAPEUTIC CATEGORIES —
  • Addiction/dependence
  • Narcotic analgesics

Methadone Generic Name & Formulations

General Description

Methadone HCl 5mg, 10mg; scored tabs.

Pharmacological Class

Opioid agonist.

How Supplied

Contact supplier

Methadone Indications

Indications

Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services.

Methadone Dosage and Administration

Adult

See full labeling. Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. Peak respiratory depressant effects typically occur later, and persist longer than peak analgesic effects. Induction/initial dosing: 20–30mg, an additional 5–10mg may be given if withdrawal symptoms not suppressed. Total daily dose on first day of treatment: max 40mg. Adjust dose cautiously. Short-term detoxification: titrate to total daily dose of 40mg in divided doses, continue for 2–3 days, then gradually decrease dose. Maintenance treatment: titrate to dose at which opioid withdrawal symptoms are prevented for 24hrs, drug hunger/craving is reduced, euphoric effects are blocked/attenuated, and patient is tolerant to sedative effects; usual range: 80–120mg/day. Medically supervised withdrawal after a period of maintenance treatment: dose reduction should be <10% of maintenance dose, 10–14 day intervals should elapse between dose reductions. Pregnancy: may need dose increase. Concomitant use or discontinuation of CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling).

Children

<18yrs: not established.

Methadone Contraindications

Contraindications

Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.

Methadone Boxed Warnings

Boxed Warning

Addiction, abuse, and misuse. Risk evaluation and mitigation strategy (REMS). Life-threatening respiratory depression. Accidental ingestion. Life-threatening QT prolongation. Neonatal opioid withdrawal syndrome. Interactions with drugs affecting CYP450 isoenzymes. Risks from concomitant use with benzodiazepines or other CNS depressants. Treatment for opioid addiction.

Methadone Warnings/Precautions

Warnings/Precautions

May only be dispensed by opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration and approved by designated state authority. Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Accidental exposure may cause fatal overdose (esp. in children). Sleep-related breathing disorders (including central sleep apnea (CSA), sleep-related hypoxemia); consider dose reduction if CSA develops. COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). Life-threatening QT prolongation and serious arrhythmia; monitor for cardiac rhythm changes in high-risk patients (eg. cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), history of cardiac conduction abnormalities, and those taking drugs affecting cardiac conduction. Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Drug abusers. Renal or hepatic impairment: initiate at lower doses. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Labor & delivery: not recommended. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Nursing mothers: monitor infants.

REMS

YES

Methadone Pharmacokinetics

See Literature

Methadone Interactions

Interactions

Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); if for pain, reserve concomitant use in those for whom alternative options are inadequate or limit dosages/durations to minimum required; if for opioid addiction, manage concomitant use as clinically appropriate and closely monitor. Consider prescribing naloxone if concomitant use with benzodiazepines or other CNS depressants is warranted. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, cyclobenzaprine, metaxalone, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms. Potentiated by macrolides, azole antifungals, protease inhibitors, fluvoxamine, sertraline, and other CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors. Antagonized by rifampin, carbamazepine, phenytoin, St. John's Wort, phenobarbital, abacavir, amprenavir, darunavir+ritonavir, efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir, saquinavir+ritonavir, tipranivir+ritonavir, and other CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducers. Caution with drugs that prolong the QT interval (eg, Class I and III antiarrhythmics, neuroleptics, TCAs, CCBs) and drugs capable of inducing electrolyte disturbances (eg, diuretics, laxatives, mineralcorticoid hormones). May potentiate zidovudine, desipramine. May antagonize diuretics, didanosine, stavudine; monitor. Paralytic ileus may occur with anticholinergics. Diphenhydramine, doxylamine, clomipramine, chlorpromazine, thioridazine, quetiapine, verapamil may cause false (+) methadone drug screens.

Methadone Adverse Reactions

Adverse Reactions

Lightheadedness, dizziness, sedation, nausea, vomiting, sweating; respiratory depression, severe hypotension, syncope, QT prolongation.

Methadone Clinical Trials

See Literature

Methadone Note

Notes

Formerly known under the brand name Dolophine.

Methadone Patient Counseling

See Literature

Methadone Generic Name & Formulations

General Description

Methadone HCl 5mg, 10mg; scored tabs.

Pharmacological Class

Opioid agonist.

How Supplied

Contact supplier

Methadone Indications

Indications

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate.

Limitations of Use

Not for use as an as-needed (prn) analgesic. Use only if alternative treatment options (eg, non-opioid analgesics, immediate-release opioids) are ineffective, not tolerated, or otherwise inadequate to provide sufficient management of pain.

Methadone Dosage and Administration

Adult

See full labeling. Use lowest effective dose for shortest duration. Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. Peak respiratory depressant effects typically occur later, and persist longer than peak analgesic effects. Individualize. Opioid-naive: initially 2.5mg every 8–12hrs. May increase dose every 3–5 days; titrate slowly. Conversion from other oral opioids: discontinue all other around-the-clock opioids when Dolophine is initiated; deaths have occurred in opioid-tolerant patients during conversion (see full labeling). Conversion from parenteral methadone: use a 1:2 mg for parenteral to oral methadone ratio. Pregnancy: may need dose increase. Concomitant use or discontinuation of CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling). Withdraw gradually (esp. if opioid-dependent), taper by ≤10–25% every 2–4 weeks.

Children

<18yrs: not established.

Methadone Contraindications

Contraindications

Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.

Methadone Boxed Warnings

Boxed Warning

Addiction, abuse, and misuse. Risk evaluation and mitigation strategy (REMS). Life-threatening respiratory depression. Accidental ingestion. Life-threatening QT prolongation. Neonatal opioid withdrawal syndrome. Interactions with drugs affecting CYP450 isoenzymes. Risks from concomitant use with benzodiazepines or other CNS depressants. Treatment for opioid addiction.

Methadone Warnings/Precautions

Warnings/Precautions

Assess the potential need for access to naloxone when initiating and renewing therapy. Consider prescribing naloxone based on risk factors for overdose (eg, history of opioid use disorder, prior opioid overdose, household members or other close contacts at risk for accidental ingestion or overdose). Abuse potential (monitor). Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Accidental exposure may cause fatal overdose (esp. in children). Sleep-related breathing disorders (including central sleep apnea (CSA), sleep-related hypoxemia); consider dose reduction if CSA develops. COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Life-threatening QT prolongation and serious arrhythmia; monitor for cardiac rhythm changes in high-risk patients (eg. cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), history of cardiac conduction abnormalities, and those taking drugs affecting cardiac conduction. Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Drug abusers. Renal or hepatic impairment: initiate at lower doses. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Labor & delivery. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Nursing mothers: monitor infants.

REMS

YES

Methadone Pharmacokinetics

See Literature

Methadone Interactions

Interactions

Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); if for pain, reserve concomitant use in those for whom alternative options are inadequate or limit dosages/durations to minimum required; if for opioid addiction, manage concomitant use as clinically appropriate and closely monitor. Consider prescribing naloxone if concomitant use with benzodiazepines or other CNS depressants is warranted. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, cyclobenzaprine, metaxalone, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms. Potentiated by macrolides, azole antifungals, protease inhibitors, fluvoxamine, sertraline, and other CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors. Antagonized by rifampin, carbamazepine, phenytoin, St. John's Wort, phenobarbital, abacavir, amprenavir, darunavir+ritonavir, efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir, saquinavir+ritonavir, tipranivir+ritonavir, and other CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducers. Caution with drugs that prolong the QT interval (eg, Class I and III antiarrhythmics, neuroleptics, TCAs, CCBs) and drugs capable of inducing electrolyte disturbances (eg, diuretics, laxatives, mineralcorticoid hormones). May potentiate zidovudine, desipramine. May antagonize diuretics, didanosine, stavudine; monitor. Paralytic ileus may occur with anticholinergics. Diphenhydramine, doxylamine, clomipramine, chlorpromazine, thioridazine, quetiapine, verapamil may cause false (+) methadone drug screens.

Methadone Adverse Reactions

Adverse Reactions

Lightheadedness, dizziness, sedation, nausea, vomiting, sweating; respiratory depression, severe hypotension, syncope, QT prolongation.

Methadone Clinical Trials

See Literature

Methadone Note

Notes

Formerly known under the brand name Dolophine.

Methadone Patient Counseling

See Literature